V Semiglazov Selected Research

V Semiglazov Research Topics

13	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2007
4	Pathologic Complete Response 01/2022 - 02/2015
4	Neoplasms (Cancer) 01/2017 - 12/2007
3	Disease Progression 01/2021 - 01/2012
2	Triple Negative Breast Neoplasms 01/2022 - 01/2021
2	Inflammatory Breast Neoplasms 02/2015 - 10/2011
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2017
1	Residual Neoplasm 01/2017
1	Febrile Neutropenia 01/2016
1	Neutropenia 09/2015
1	Hypertension (High Blood Pressure) 01/2012

5	Trastuzumab (Herceptin)FDA Link 01/2018 - 10/2011
4	Docetaxel (Taxotere)FDA Link 01/2016 - 03/2012
2	atezolizumabIBA 01/2022 - 01/2021
2	taxaneIBA 01/2021 - 02/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 02/2014
2	Biosimilar PharmaceuticalsIBA 01/2018 - 09/2015
2	ErbB Receptors (EGF Receptor)IBA 01/2018 - 02/2014
1	B7-H1 AntigenIBA 01/2021
1	Albumin-Bound Paclitaxel FDA Link 01/2021
1	Diphosphonates (Bisphosphonates)IBA 01/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016
1	Monoclonal AntibodiesIBA 12/2015
1	pertuzumabIBA 12/2015
1	Filgrastim (Neupogen)FDA Link 09/2015
1	AZD 8931IBA 02/2014
1	human ERBB2 proteinIBA 02/2014
1	AnthracyclinesIBA 03/2012
1	Capecitabine (Xeloda)FDA Link 03/2012
1	Bevacizumab (Avastin)FDA Link 01/2012
1	Epidermal Growth Factor (EGF)IBA 01/2012
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2007
1	Hormones (Hormone)IBA 01/2007
1	Fulvestrant (Faslodex)FDA Link 01/2007